Nilotinib is an oral medication, and approved to target the BCR-ABL tyrosine kinase protein. It can be used as a first treatment for chronic myeloid leukemia (CML) or as an alternative for patients who experience side effects from imatinib or because imatinib isn’t working. Nilotinib can be used to treat Chronic, Accelerated, and Blast Phase CML.
Common Side Effects:
These side effects are common when patients start therapy but are usually mild to moderate. Most of these side effects improve over time but it is important to tell your doctor about any side effects you may be experiencing. Supportive medications can help with symptoms from these side effects and often, the TKI doses do not need to be modified.
Potential Serious side effects:
Additional Information: https://medlineplus.gov/druginfo/meds/a608002.html